9 results on '"Hiwasa, Takaki"'
Search Results
2. Analysis of patients with colorectal cancer shows a specific increase in serum anti-ING1 autoantibody levels
- Author
-
Arasawa, Takahiro, Hiwasa, Takaki, Kagaya, Akiko, Maruyama, Tetsuro, Uesato, Masaya, Kano, Masayuki, Kobayashi, Sohei, Takizawa, Hirotaka, Iwase, Katsuro, Nomura, Fumio, Matsushita, Kazuyuki, and Matsubara, Hisahiro
- Published
- 2023
- Full Text
- View/download PDF
3. Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke
- Author
-
Hiwasa, Takaki, Wang, Hao, Goto, Ken-ichiro, Mine, Seiichiro, Machida, Toshio, Kobayashi, Eiichi, Yoshida, Yoichi, Adachi, Akihiko, Matsutani, Tomoo, Sata, Mizuki, Yamagishi, Kazumasa, Iso, Hiroyasu, Sawada, Norie, Tsugane, Shoichiro, Kunimatsu, Mitoshi, Kamitsukasa, Ikuo, Mori, Masahiro, Sugimoto, Kazuo, Uzawa, Akiyuki, Muto, Mayumi, Kuwabara, Satoshi, Kobayashi, Yoshio, Ohno, Mikiko, Nishi, Eiichiro, Hattori, Akiko, Yamamoto, Masashi, Maezawa, Yoshiro, Kobayashi, Kazuki, Ishibashi, Ryoichi, Takemoto, Minoru, Yokote, Koutaro, Takizawa, Hirotaka, Kishimoto, Takashi, Matsushita, Kazuyuki, Kobayashi, Sohei, Nomura, Fumio, Arasawa, Takahiro, Kagaya, Akiko, Maruyama, Tetsuro, Matsubara, Hisahiro, Tomiita, Minako, Hamanaka, Shinsaku, Imai, Yushi, Nakagawa, Tomoo, Kato, Naoya, Terada, Jiro, Matsumura, Takuma, Katsumata, Yusuke, Naito, Akira, Tanabe, Nobuhiro, Sakao, Seiichiro, Tatsumi, Koichiro, Ito, Masaaki, Shiratori, Fumiaki, Sumazaki, Makoto, Yajima, Satoshi, Shimada, Hideaki, Shirouzu, Mikako, Yokoyama, Shigeyuki, Kudo, Takashi, Doi, Hirofumi, Iwase, Katsuro, Ashino, Hiromi, Li, Shu-Yang, Kubota, Masaaki, Tomiyoshi, Go, Shinmen, Natsuko, Nakamura, Rika, Kuroda, Hideyuki, and Iwadate, Yasuo
- Published
- 2021
- Full Text
- View/download PDF
4. Association of serum levels of antibodies against ALDOA and FH4 with transient ischemic attack and cerebral infarction
- Author
-
Wang, Hao, Lu, Hao, Zhang, Xiao-Meng, Goto, Ken-ichiro, Kobayashi, Eiichi, Yoshida, Yoichi, Adachi, Akihiko, Matsutani, Tomoo, Iwadate, Yasuo, Mine, Seiichiro, Machida, Toshio, Sata, Mizuki, Yamagishi, Kazumasa, Iso, Hiroyasu, Sawada, Norie, Tsugane, Shoichiro, Kamitsukasa, Ikuo, Wada, Takeshi, Aotsuka, Akiyo, Sugimoto, Kazuo, Takizawa, Hirotaka, Kashiwado, Koichi, Shin, Hideo, Tomiyoshi, Go, Nakamura, Rika, Shinmen, Natsuko, Kuroda, Hideyuki, Xu, Anding, and Hiwasa, Takaki
- Published
- 2021
- Full Text
- View/download PDF
5. Identification of a novel SEREX antigen family, ECSA, in esophageal squamous cell carcinoma.
- Author
-
Kagaya, Akiko, Shimada, Hideaki, Shiratori, Tooru, Kuboshima, Mari, Nakashima-Fujita, Kazue, Yasuraoka, Mari, Nishimori, Takanori, Kurei, Shunsuke, Hachiya, Takahisa, Murakami, Akihiro, Tamura, Yutaka, Nomura, Fumio, Ochiai, Takenori, Matsubara, Hisahiro, Takiguchi, Masaki, and Hiwasa, Takaki
- Subjects
SQUAMOUS cell carcinoma ,TUMOR markers ,ANTIGENS ,ENZYME-linked immunosorbent assay ,AMINO acid sequence ,IMMUNOGLOBULINS ,TUMORS - Abstract
Background: Diagnosis of esophageal squamous cell carcinoma (SCC) may improve with early diagnosis. Currently it is difficult to diagnose SCC in the early stage because there is a limited number of tumor markers available. Results: Fifty-two esophageal SCC SEREX antigens were identified by SEREX (serological identification of antigens by recombinant cDNA expression cloning) using a cDNA phage library and sera of patients with esophageal SCC. Sequence analysis revealed that three of these antigens were similar in amino acid sequences, and they were designated as ECSA (esophageal carcinoma SEREX antigen)-1, -2 and -3. The ECSA family was also similar to an EST clone, hepatocellular carcinoma-associated antigen 25a (HCA25a). Serum antibody levels to ECSA-1, -2 and -3 were significantly higher in patients with esophageal SCC than in healthy donors. Based on the conserved amino acid sequences, three peptides were synthesized and used for enzyme-linked immunosorbent assays (ELISA). The serum antibody levels against one of these peptides were significantly higher in patients with esophageal SCC. This peptide sequence was also conserved in FAM119A, GOSR1 and BBS5, suggesting that these are also ECSA family members. Reverse transcription followed by quantitative PCR analysis showed that the mRNA expression levels of ECSA-1, -2 and -3 and FAM119A but not of HCA25a, GOSR1 and BBS5 were frequently elevated in esophageal SCC tissues. Conclusions: We have identified a new gene family designated ECSA. Serum antibodies against the conserved domain of the ECSA family may be a promising tumor marker for esophageal SCC. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
6. Identification of stroke-associated-antigens via screening of recombinant proteins from the human expression cDNA library (SEREX).
- Author
-
Machida T, Kubota M, Kobayashi E, Iwadate Y, Saeki N, Yamaura A, Nomura F, Takiguchi M, and Hiwasa T
- Subjects
- Aged, Antibodies metabolism, Blotting, Western, Cohort Studies, Electrophoresis, Polyacrylamide Gel, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunohistochemistry, Male, Middle Aged, Peptides metabolism, ROC Curve, Reproducibility of Results, Antigens metabolism, Gene Library, Recombinant Proteins metabolism, Stroke immunology
- Abstract
Background: Because circulating antibodies against a variety of antigens have been detected in patients with coronary heart disease, carotid atherosclerosis and those who have suffered a stroke, it is suspected that immune response may be one of the mechanisms of atherogenesis The objective of this study is to identify novel antibodies in ischemic stroke patients by screening the expressed recombinant proteins using a human cDNA library (SEREX)., Methods: To identify the candidate antigens, cDNA library was screened by SEREX using plasma from ten patients with ischemic stroke. Subsequently, via ELISA using recombinant proteins and synthetic peptides, the serum antibody levels were measured in two independent patient/healthy donor (HD) cohorts (142 and 78 in the 2nd screening and a validation cohort, respectively)., Results: The initial screening resulted in the identification of six candidate antigens. Of these antigens, replication protein A2 (RPA2) was determined to be the antigen associated with stroke (P < 0.05) by ELISA with 2nd screening and validation cohort. Multifactorial logistic regression analysis showed that the increased levels of the RPA2 antibodies (RPA2-Abs) associated with stroke independent of other risk factors for stroke (P < 0.05). Receiver operating curve analysis demonstrated that the area under the curve from ELISA using GST fusion RPA2 and synthetic peptides (bRPA2-132) were 0.867 (95% CI: 0.798-0.936) and 0.971 (95% CI: 0.940-1.00), respectively. If the cut-off value of the bRPA2-132-Ab level was determined to be 0.334, the sensitivity and specificity of the antibody level as the diagnostic marker for stroke were 0.323 (95% CI: 0.209-0.453) and 1.00 (95% CI: 0.713-1.00), respectively., Conclusions: SEREX identified RPA2 as the antigen associated with ischemic stroke and serum auto-antibodies against RPA2 elevates in stroke patients. RPA2-Abs could become a biomarker for the evaluation of ischemic stroke at risk.
- Published
- 2015
- Full Text
- View/download PDF
7. Circulating anti-filamin C autoantibody as a potential serum biomarker for low-grade gliomas.
- Author
-
Adachi-Hayama M, Adachi A, Shinozaki N, Matsutani T, Hiwasa T, Takiguchi M, Saeki N, and Iwadate Y
- Subjects
- Adolescent, Adult, Aged, Child, Female, Filamins genetics, Filamins metabolism, Gene Expression Regulation, Neoplastic, Glioma blood, Humans, Male, Middle Aged, Young Adult, Autoantibodies blood, Biomarkers, Tumor blood, Filamins immunology, Glioma pathology
- Abstract
Background: Glioma is the most common primary malignant central nervous system tumor in adult, and is usually not curable due to its invasive nature. Establishment of serum biomarkers for glioma would be beneficial both for early diagnosis and adequate therapeutic intervention. Filamins are an actin cross-linker and filamin C (FLNC), normally restricted in muscle tissues, offers many signaling molecules an essential communication fields. Recently, filamins have been considered important for tumorigenesis in cancers., Methods: We searched for novel glioma-associated antigens by serological identification of antigens utilizing recombinant cDNA expression cloning (SEREX), and found FLNC as a candidate protein. Tissue expressions of FLNC (both in normal and tumor tissues) were examined by immunohistochemistry and quantitative RT-PCR analyses. Serum anti-FLNC autoantibody level was measured by ELISA in normal volunteers and in the patients with various grade gliomas., Results: FLNC was expressed in glioma tissues and its level got higher as tumor grade advanced. Anti-FLNC autoantibody was also detected in the serum of glioma patients, but its levels were inversely correlated with the tissue expression. Serum anti-FLNC autoantibody level was significantly higher in low-grade glioma patients than in high-grade glioma patients or in normal volunteers, which was confirmed in an independent validation set of patients' sera. The autoantibody levels in the patients with meningioma or cerebral infarction were at the same level of normal volunteers, and they were significantly lower than that of low-grade gliomas. Total IgG and anti-glutatione S-transferase (GST) antibody level were not altered among the patient groups, which suggest that the autoantibody response was specific for FLNC., Conclusions: The present results suggest that serum anti-FLNC autoantibody can be a potential serum biomarker for early diagnosis of low-grade gliomas while it needs a large-scale clinical study.
- Published
- 2014
- Full Text
- View/download PDF
8. Autologous antibody to src-homology 3-domain GRB2-like 1 specifically increases in the sera of patients with low-grade gliomas.
- Author
-
Matsutani T, Hiwasa T, Takiguchi M, Oide T, Kunimatsu M, Saeki N, and Iwadate Y
- Subjects
- Animals, Antibody Specificity immunology, Antigens, Neoplasm genetics, Antigens, Neoplasm immunology, Brain Neoplasms blood, Brain Neoplasms mortality, Brain Neoplasms pathology, Cell Line, Tumor, Disease Models, Animal, Epitopes immunology, Gene Library, Glioma blood, Glioma mortality, Glioma pathology, Humans, Intracellular Signaling Peptides and Proteins chemistry, Intracellular Signaling Peptides and Proteins genetics, Neoplasm Grading, Rats, Reproducibility of Results, Antibodies blood, Antibodies immunology, Brain Neoplasms immunology, Glioma immunology, Intracellular Signaling Peptides and Proteins immunology
- Abstract
Background: Glioma is the most common primary malignant central nervous system tumor in adult, and is usually not curable in spite of various therapeutic approaches. Clarification of the oncogenic process in its early stage is important for the diagnosis and effective therapy., Methods: In the present study, we used the serological identification of antigens by recombinant cDNA expression cloning (SEREX) to explore the subtle changes of the protein expression in low-grade glioma. The levels of serum autoantibodies to the SEREX-identified glioma-related antigens were analyzed by ELISA, and the epitope site was identified using deletion mutants and overlap peptide array. Changes in the serum autoantibody levels were examined in the rat glioma model using C6 and 9 L glioma cell lines., Results: We identified 31 glioma-related antigens by SEREX. Among them, the serum level of autoantibody to src-homology 3-domain GRB2-like 1 (SH3GL1) was significantly higher in patients with low-grade glioma than healthy volunteers or high-grade gliomas. The 10 amino-acids at the C-terminal were identified as the epitope site by the overlap peptide array and the ELISA using deletion mutants. The tissue expression of SH3GL1 protein increased in proportion to glioma progression. The rat glioma models confirmed the increase of anti-SH3GL1 autoantibody level in the early stage and the suppression in the late stage., Conclusion: SH3GL1 may be involved in the oncogenic process of gliomas and effectively elicit an autologous antibody response in low-grade gliomas. The immunological reaction to SH3GL1 would contribute to the establishment of a novel diagnostic and therapeutic target for gliomas.
- Published
- 2012
- Full Text
- View/download PDF
9. Identification of Makorin 1 as a novel SEREX antigen of esophageal squamous cell carcinoma.
- Author
-
Shimada H, Shiratori T, Yasuraoka M, Kagaya A, Kuboshima M, Nomura F, Takiguchi M, Ochiai T, Matsubara H, and Hiwasa T
- Subjects
- Animals, Cloning, Molecular, DNA, Complementary metabolism, Gene Library, Humans, Mice, NIH 3T3 Cells, RNA, Messenger metabolism, Antigens, Neoplasm metabolism, Biomarkers, Tumor metabolism, Carcinoma, Squamous Cell metabolism, Esophageal Neoplasms metabolism, Gene Expression Profiling methods, Gene Expression Regulation, Neoplastic, Nerve Tissue Proteins biosynthesis, Ribonucleoproteins biosynthesis
- Abstract
Background: Esophageal squamous cell carcinoma (SCC) represents one of the most malignant tumors. To improve the poor prognosis, it is necessary to diagnose esophageal SCC at early stages using new tumor markers. SEREX (serological identification of antigens by recombinant cDNA expression cloning) is suitable for large-scale screening of tumor antigens and has been applied for various types of human tumors., Methods: Tumor markers of esophageal squamous cell carcinoma (SCC) were screened by SEREX method. The presence of serum anti-makorin 1 (MKRN1) antibodies (s-MKRN1-Abs) was examined by Western blotting using bacterially expressed MKRN1 protein. The expression levels of MKRN1 mRNA in tissues were examined by RT-PCR. The biological activity of MKRN1 was examined by transfection of ras-NIH3T3 mouse fibroblasts with MKRN1 cDNA. Major ubiquitinated proteins in MKRN1-transfected cells were identified by immunoprecipitation with anti-ubiquitin antibody followed by mass spectrometry., Results: MKRN1 was identified as a novel SEREX antigen of esophageal SCC. Although a total of 18 (25%) of 73 patients with esophageal SCC had s-MKRN1-Abs, none of the 43 healthy donors had a detectable level of s-MKRN1-Abs. There was no correlation between the presence of s-MKRN1-Abs and clinicopathological variables other than histological grading. Well-differentiated tumors were associated significantly with the presence of s-MKRN1-Abs in the patients. The mRNA levels of MKRN1 were frequently higher in esophageal SCC tissues than in the peripheral normal esophageal mucosa. Stable transfection of ras-NIH3T3 cells with MKRN1 cDNA induced prominent morphological changes such as enlargement of the cell body and spreading. Ubiquitination of 80- and 82-kDa proteins were clearly observed in MKRN1-transfected cells but not in the parental cells, which were identified as L-FILIP (filamin A interacting protein 1)., Conclusion: MKRN1 is a novel SEREX antigen of esophageal SCC, and s-NKRN1-Abs can be a candidate of diagnostic markers of esophageal SCC with high specificity. It is plausible that MKRN1 is involved in carcinogenesis of the well-differentiated type of tumors possibly via ubiquitination of L-FILIP.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.